Table 3 DMT uptake and usage pattern within RRMS patients.
Chinese (n = 82) | Malay (n = 32) | South Asian (n = 63) | Total (n = 177) | p-value | |
|---|---|---|---|---|---|
DMT usage (%) | |||||
Yes | 60 (73.2) | 22 (68.8) | 49 (77.8) | 131 (74.0) | |
No | 22 (26.8) | 10 (31.3) | 14 (22.2) | 46 (26.0) | 0.467 |
Efficacy of first DMT (%) | |||||
High | 23 (38.3) | 4 (18.2) | 17 (34.7) | 44 (33.6) | |
Low-to-moderate | 37 (61.7) | 18 (81.8) | 32 (65.3) | 87 (66.4) | 0.248 |
Type of first DMT (%) | |||||
Interferons | 33 (55.5) | 17 (77.3) | 22 (44.9) | 72 (55.0) | |
Glatiramer acetate | 1 (1.7) | – | 2 (4.1) | 3 (2.3) | |
Teriflunomide | 1 (1.7) | – | 2 (4.1) | 3 (2.3) | |
Dimethyl fumarate | – | 1 (4.5) | 3 (6.1) | 4 (3.1) | |
Leflunomide | 1 (1.7) | – | 1 (2.0) | 2 (1.5) | |
Azathioprine | 1 (1.7) | 1 (4.5) | 1 (2.0) | 3 (2.3) | |
Fingolimod | 2 (3.3) | – | 4 (8.2) | 6 (4.6) | |
Cladribine | 6 (10.0) | – | 5 (10.2) | 11 (8.4) | |
Alemtuzumab | 1 (1.7) | 3 (13.6) | 1 (2.0) | 5 (3.8) | |
Natalizumab | 5 (8.3) | – | 1 (2.0) | 6 (4.6) | |
Rituximab | 7 (11.7) | – | 5 (10.2) | 12 (9.2) | |
Ocrelizumab | 2 (3.3) | – | 1 (2.0) | 3 (2.3) | |
Secukinumab | – | – | 1 (2.0) | 1 (0.8) | 0.458 |
Time taken to initiate DMT from MS diagnosis in days, median (Q1, Q3) | 241 (30.5, 975) | 152 (28.5, 568) | 121 (28, 527) | 124 (29, 731) | 0.535 |
Percentage time on DMT, median (Q1, Q3) | |||||
High efficacy | 36.4 (6.5, 74.2) | 30.7 (0.0, 53.2) | 26.5 (0.0, 59.1) | 30.0 (0.3, 61.5) | 0.225 |
Low-to-moderate efficacy | 9.9 (0.0, 41.4) | 19.9 (9.0, 58.3) | 19.6 (0.0, 52.7) | 16.6 (0.0, 48.1) | 0.188 |
All DMTs | 69.8 (46.1, 94.1) | 58.0 (37.8, 86.5) | 68.7 (31.9, 95.3) | 65.8 (38.3, 93.1) | 0.661 |
Number of DMT changes, median (Q1, Q3) | 1.0 (0.0, 1.0) | 1.0 (1.0, 2.0) | 1.0 (0.0, 1.5) | 1.0 (0.0, 1.0) | 0.126 |
Switched out of initial DMT (%) | |||||
Yes | 32 (53.3) | 18 (81.8) | 27 (55.1) | 70 (56.0) | |
No | 28 (46.7) | 4 (18.2) | 22 (44.9) | 55 (44.0) | 0.051 |
